{"organizations": [], "uuid": "b3200b2b6d3c7fb595e8ae03ff59eedc38652a3d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/23/globe-newswire-sarepta-therapeutics-to-announce-first-quarter-2018-financial-results-and-recent-corporate-devel-opments-on-may-3-2018.html", "country": "US", "domain_rank": 767, "title": "Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and Recent Corporate Devel-opments on May 3, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.007, "site_type": "news", "published": "2018-04-23T16:30:00.000+03:00", "replies_count": 0, "uuid": "b3200b2b6d3c7fb595e8ae03ff59eedc38652a3d"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/23/globe-newswire-sarepta-therapeutics-to-announce-first-quarter-2018-financial-results-and-recent-corporate-devel-opments-on-may-3-2018.html", "ord_in_thread": 0, "title": "Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and Recent Corporate Devel-opments on May 3, 2018", "locations": [], "entities": {"persons": [{"name": "sarepta", "sentiment": "none"}], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "cambridge", "sentiment": "none"}, {"name": "sarepta", "sentiment": "none"}], "organizations": [{"name": "sarepta therapeutics", "sentiment": "negative"}, {"name": "sarepta therapeutics, inc.", "sentiment": "neutral"}, {"name": "eastern time", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, will report first quarter 2018 financial results after the Nasdaq Global Market closes on Thursday, May 3, 2018. Subsequently, at 4:30 p.m. Eastern Time, the Company will host a conference call to discuss its first quarter 2018 financial results and to provide a corporate update.\nThe conference call may be accessed by dialing 844-534-7313 for domestic callers and +1-574-990-1451 for international callers. The passcode for the call is 2798939. Please specify to the operator that you would like to join the \"Sarepta First Quarter 2018 Earnings Call\". The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.\nAbout Sarepta Therapeutics\nSarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com .\nInternet Posting of Information\nWe routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com . We encourage investors and potential investors to consult our website regularly for important information about us.\nSource: Sarepta Therapeutics, Inc.\nMedia and Investors:\nSarepta Therapeutics, Inc.\nIan Estepan, 617-274-4052\niestepan@sarepta.com\nor\nW2O Group\nBrian Reid, 212-257-6725\nbreid@w2ogroup.com\nSource:Sarepta Therapeutics, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=_lvcufbRRJdX79Gf3nDssGWL3_Gp29SVz70oiEvyZkd44GOA8ngswH0gZ4sKVKc7jOCCYYtWZ8ozrtn7eNyANxHIECkFzOqZl4r7c1LyU9g=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/7cc27c43-de1a-41c5-bbce-6ca95676ea69", "https://www.globenewswire.com/Tracker?data=H_rAr63vDxvR8TtAn_-cGSfF6dkUHxAsyDhr-_gdQZJ8AGGf6iamV2dn-neO2U8ZXT-qagw73BugPhiNTz7Z5g==", "https://www.globenewswire.com/Tracker?data=H_rAr63vDxvR8TtAn_-cGd6b2abXod7roszTJ_tPO7Mo3bzPz-kSTBPiUSMLZMHv4SU5e72xhSlNscVHYijiiw==", "https://www.globenewswire.com/Tracker?data=Vntuc2lNyoO-nzGlSAId1ts0-zPac_gvn5fIBjbcBKkrdb6e896whKURJK6SVjjfN-uJnjGxAlOk0eREjXmyuL1noDndyrP_7zbFaybnaAM=", "https://www.globenewswire.com/Tracker?data=H_rAr63vDxvR8TtAn_-cGVIZJZpK24RhL8SgmZmOIB9ax3e2He7Y-R3kMiu9uLkbwNdtMbJBoU-72ox4mnIJ8w=="], "published": "2018-04-23T16:30:00.000+03:00", "crawled": "2018-04-23T17:20:14.019+03:00", "highlightTitle": ""}